An anti-double-stranded DNA monoclonal antibody induced by tumor cell-derived DNA inhibits the growth of tumor in vitro and in vivo via triggering apoptosis.
Serological presence of anti-double-stranded DNA (anti-dsDNA) antibodies is a common phenomenon in cancer patients. Some patients with relatively high levels of anti-dsDNA antibodies may have a better prognosis, indicating the potential antitumor roles of anti-dsDNA antibodies. To delineate the role and mechanisms of anti-dsDNA antibodies in delaying tumor development, here we prepared a panel of anti-dsDNA monoclonal antibodies (mAbs) and assessed their antitumor effects both in vitro and in vivo. After immunization of BALB/c mice with DNA from SP2/0 tumor cells, 12 anti-dsDNA mAbs were obtained. Among these mAbs, mAb 2G8 exhibited the strongest cytotoxicity to Wehi164 cells in vitro and significantly inhibited the growth of tumor in vivo. This mAb 2G8-mediated antitumor effect was mainly exerted by triggering apoptosis, as evidenced by Annexin V staining and DNA fragmentation. Further, the expression of antiapoptotic genes Bcl-2 and Bcl-xL was downregulated while that of pro-apoptotic gene Bax was upregulated, suggesting the involvement of mitochondrial apoptotic pathway. Taken together, dsDNA-specific mAb 2G8 revealed promising tumor-suppressive activity by inducing apoptosis, which provides a possible new strategy for the development of tumor intervening methods.